EpiCast Report: Growth Hormone Deficiency - Epidemiology Forecast to 2026

  • ID: 4315771
  • Drug Pipelines
  • 36 pages
  • GlobalData
1 of 3
EpiCast Report: Growth Hormone Deficiency - Epidemiology Forecast to 2026

Summary

GHD is an endocrine disorder characterized by the insufficient production of GH by the pituitary gland (CGF, 2003). The ICD-10 Clinical Modification (ICD-10-CM) code for GHD is E23.0. GHD is more commonly seen in children, although it can develop during adulthood. GHD can be present from birth, in which case it is known as congenital, or it can be secondary due to brain trauma and is known as acquired. The signs and symptoms of the disease can vary. Generally, a child with GHD is born with normal size at birth, but has delayed rates of bone development and bone lengthening later on. GHD in children affects growth and development.

In the 7MM, the diagnosed prevalent cases of GHD for all ages and both sexes will increase from 109,551 cases in 2016 to 112,450 cases in 2026 at an Annual Growth Rate (AGR) of 0.26%. Our epidemiologists forecast an increase in the diagnosed prevalent cases of GHD in all markets except Germany and Japan.

In 2016, the US made up about 48% of all diagnosed prevalent cases of GHD in the 7MM. In 2016, the 5EU made up approximately 40%, and Japan made up nearly 13%, of all cases of GHD in the 7MM. Our epidemiologists maintained a consistent forecast methodology across all the 7MM, which allows for comparison between each of the seven markets. Due to the limited availability of market-specific epidemiological studies available, further research is needed to better understand inter-market variations of the epidemiological parameters.

The report "EpiCast Report: Growth Hormone Deficiency - Epidemiology Forecast to 2026" provides an overview of the risk factors, comorbidities, and global trends for GHD in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for the diagnosed prevalent cases of GHD in children (ages 18 years and younger) and adults (ages 19 years and older) segmented by age and sex from 2016 to 2026. The diagnosed prevalent cases of GHD are further segmented into the classification of the disease (idiopathic and organic in children, and idiopathic and acquired in adults). Organic GHD in children is further segmented into congenital and acquired. GHD in adults is segmented by timing of disease onset: childhood onset GHD (COGHD) and adult onset GHD (AOGHD).

Scope
  • The Growth Hormone Deficiency (GHD) EpiCast Report provides an overview of the risk factors, comorbidities, and global trends of GHD in the 7MM (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for the diagnosed prevalent cases of GHD in children (ages 18 years and younger) and adults (ages 19 years and older) segmented by age and sex. The diagnosed prevalent cases of GHD are further segmented into the classification of the disease (idiopathic and organic in children, and idiopathic and acquired in adults). Organic GHD in children is further segmented into congenital and acquired. GHD in adults is segmented by timing of disease onset: childhood onset GHD and adult onset GHD.
  • The GHD epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.
Reasons to buy

The GHD EpiCast report will allow you to:
  • Develop business strategies by understanding the trends shaping and driving the global GHD market.
  • Quantify patient populations in the global GHD market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for GHD therapeutics in each of the markets covered.
  • Identify the percentage of GHD diagnosed prevalent cases by various clinical segmentations.
READ MORE
Note: Product cover images may vary from those shown
2 of 3
1 Table of Contents
2 Executive Summary
2.1 Related Reports
2.2 Upcoming Reports
3 Epidemiology
3.1 Disease Background
3.2 Risk Factors and Comorbidities
3.3 Global and Historical Trends
3.3.1 GHD in children
3.3.2 GHD in adults
3.4 Forecast Methodology
3.4.1 Sources
3.4.2 Forecast Assumptions and Methods
3.5 Epidemiological Forecast for GHD (2016-2026)
3.5.1 Diagnosed Prevalent Cases of GHD
3.5.2 Age-Specific Diagnosed Prevalent Cases of GHD
3.5.3 Sex-Specific Diagnosed Prevalent Cases of GHD
3.5.4 Idiopathic and Organic GHD in Children
3.5.5 Congenital and Acquired GHD Out of Organic GHD in Children
3.5.6 Idiopathic and Acquired GHD in Adults
3.5.7 Onset Timing
3.6 Discussion
3.6.1 Epidemiological Forecast Insight
3.6.2 Limitations of Analysis
3.6.3 Strengths of the Analysis
4 Appendix
4.1 Bibliography
4.2 About the Authors
4.2.1 Epidemiologist
4.2.2 Reviewers
4.2.3 Global Director of Therapy Analysis and Epidemiology
4.2.4 Global Head and EVP of Healthcare Operations and Strategy
4.3 About
4.4 Contact
4.5 Disclaimer

List of Tables
Table 1: Risk Factors and Comorbidities for GHD
Table 2: Diagnosed Prevalent Cases of GHD, Men and Women, All Ages, for 2016-2026.

List of Figures
Figure 1: 7MM, Diagnosed Prevalent Cases of GHD, Both Sexes, All Ages, 2016 and 2026
Figure 2: Age-Standardized Diagnosed Prevalence of GHD, Men and Women, All Ages, 2016
Figure 3: Case Flow Map of GHD
Figure 4: Sources Used and Not Used for the Diagnosed Prevalent Cases of GHD in Children
Figure 5: Sources Used and Not Used in the Forecast for Diagnosed Prevalent Cases of GHD in Adults
Figure 6 Sources Used and Not Used in the Forecast for Type of GHD in Children
Figure 7 Sources Used and Not Used in the Forecast for Type of GHD in Adults
Figure 8 Sources Used and Not Used in the Forecast for Onset Timing of GHD in Adults
Figure 9: Age-Specific Diagnosed Prevalent Cases of GHD, Men and Women, All Ages, 2016.
Figure 10: Sex-Specific Diagnosed Prevalent Cases, Men, Women, All Ages, 2016
Figure 11: Diagnosed Prevalent Cases of GHD in Children Segmented into Idiopathic and Organic GHD, Boys and Girls, Ages =18 years, 2016
Figure 12: Diagnosed Prevalent Cases of Congenital or Acquired GHD Out of Organic GHD, Boys and Girls, Ages =18 years, 2016
Figure 13: Idiopathic and Acquired GHD in Adults, Men and Women, Ages =19 Years, 2016.
Figure 14: Diagnosed Prevalent Cases by Onset Timing, Men and Women, Ages =19 Years, 2016.
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll